Gene Therapies Are Still Hampered By Substantial Delays Between Approval And Launch Gene therapies are still hampered by substantial delays between their date of approval and the time they launch. And it isn’t simply a matter of not having a payment or reimbursement system in place. Manufacturing and patient preparation delays figure prominently.